Chloroquineand hydroxychloroquine in covid 19: asystematic review

Authors

  • Najib AL IDRISSI Mohammed VI University of Health Sciences (UM6SS), University Hospital Cheikh Khalifa, Casablanca, Morocco
  • Khalid BOUTI Center of Tuberculosis and Lung Diseases, Tetouan, Morocco
  • Anissa REGRAGUI Faculty of Dental Medicine, Mohammed V University, Rabat, Morocco
  • Nezha DINI Mohammed VI University of Health Sciences (UM6SS), University Hospital Cheikh Khalifa, Casablanca, Morocco
  • Redouane RABII Mohammed VI University of Health Sciences (UM6SS), University Hospital Cheikh Khalifa, Casablanca, Morocco
  • Chakib NEJJARI Mohammed VI University of Health Sciences (UM6SS), University Hospital Cheikh Khalifa, Casablanca, Morocco

DOI:

https://doi.org/10.80481/revuetest24192

Keywords:

Chloroquine, hydroxychloroquine, Covid-19, SARS-CoV-2

Abstract

Since 100 years, current coronavirus pandemic (COVID-19) caused by SARS-CoV-2 is themostdangerous healthcare crisis and unprecedented in absense of prophylactic or therapeutic drugs. The world's major health systems have had no large-scale therapeutic choice and at an acceptable cost apart from Chloroquine (CQ) and its derivative hydroxychloroquine (HCQ) to treat Covid-19.These drugs have anti-inflammatory activity and are already used to treat rheumatoid arthritis, lupus. However, these drugs have raised a great worldwide controversy between the pros and cons of their uses to treat patientswith Covid-19In these systematic review, we analyzed articles published until 28 august in pubmed, sciences direct and ClinicalTrials.gov by using these keywords: chloroquine and COVID-19 or hydroxychloroquine and COVID-19. these online preprint publications have offered inconclusive preliminary results as well as clinical trials not yet finished. Although CQ / HCQ have antiviral activity against Sars cov 2 in vitro, antiviral activity in vivo is questionable.

Downloads

Published

25-12-2020